The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
A 4-star rating suggests above-average performance compared to other similar companies.
The economic moat refers to the competitive advantage a company has over its competitors. A narrow moat suggests that the company has a less sustainable competitive advantage compared to those with wider moats.
This ratio indicates whether the stock is trading above (greater than 1) or below (less than 1) its fair value as determined by Morningstar's quantitative analysis. A ratio of 0.94 suggests the stock is currently trading at a slight discount (undervalued).
Significant uncertainty in fair value estimates indicates substantial potential volatility in the stock price. Investors should carefully consider their risk tolerance and long-term investment strategy when evaluating stocks with this level of uncertainty.
These price estimates indicate the price levels at which Morningstar would consider the stock significantly overvalued (one-star) or undervalued (five-star) based on their analysis.
Moderate financial health suggests stability but also indicates potential risks. Evaluate the company's ability to manage its financial obligations and fund growth initiatives.
Valuation vs. Price: The stock is currently considered undervalued relative to its fair value, which could present a buying opportunity if you believe in Morningstar's valuation methodology.
Moat and Competitive Position: The narrow economic moat indicates less sustainable competitive advantages. Consider whether the company's business model and market position align with your investment goals.
Financial Health: Moderate financial health suggests stability but also indicates potential risks. Evaluate the company's ability to manage its financial obligations and fund growth initiatives.
Uncertainty: High uncertainty in fair value estimates implies potential volatility in the stock price. Factor in your risk tolerance and investment horizon when assessing this uncertainty.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu....
Moderna (MRNA) shares edged higher Tuesday after the biotech firm received a federal grant to develop a vaccine to prevent bird flu in humans....
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to co...
The U.S. government has awarded $176 million to Moderna to advance development of its bird flu vaccine, the company said on Tuesday, as concerns rise over a multi-state outbreak of H5N1 virus in dairy...
Moderna Inc.'s efforts to develop a bird-flu vaccine are getting a boost from the U.S. government, the company said Tuesday....
Moderna has secured $176 million in federal funding to develop mRNA vaccines against a potential bird flu pandemic, the Boston-based company announced Tuesday, a move that could bolster U.S. vaccine s...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the developm...
London's High Court on Tuesday ruled that one of Moderna's patents relating to technology key to the development of vaccines for COVID-19 was invalid, but that another was valid and had been infringed...
If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union....